DE3618627C2 - - Google Patents
Info
- Publication number
- DE3618627C2 DE3618627C2 DE3618627A DE3618627A DE3618627C2 DE 3618627 C2 DE3618627 C2 DE 3618627C2 DE 3618627 A DE3618627 A DE 3618627A DE 3618627 A DE3618627 A DE 3618627A DE 3618627 C2 DE3618627 C2 DE 3618627C2
- Authority
- DE
- Germany
- Prior art keywords
- prolactin
- agnus castus
- drug
- dopamine
- trh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 244000063464 Vitex agnus-castus Species 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 8
- 208000031424 hyperprolactinemia Diseases 0.000 claims description 4
- 102000003946 Prolactin Human genes 0.000 abstract description 32
- 108010057464 Prolactin Proteins 0.000 abstract description 32
- 229940097325 prolactin Drugs 0.000 abstract description 32
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 17
- 229960003638 dopamine Drugs 0.000 abstract description 14
- 230000003291 dopaminomimetic effect Effects 0.000 abstract description 13
- 235000001667 Vitex agnus castus Nutrition 0.000 abstract description 12
- 235000009347 chasteberry Nutrition 0.000 abstract description 10
- 239000012675 alcoholic extract Substances 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 239000003210 dopamine receptor blocking agent Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 238000004113 cell culture Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 238000012360 testing method Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 230000001817 pituitary effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000011534 incubation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- 210000004246 corpus luteum Anatomy 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000019395 Lactation disease Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010042576 Suppressed lactation Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 210000002596 lutein cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- QYHFIVBSNOWOCQ-UHFFFAOYSA-N selenic acid Chemical compound O[Se](O)(=O)=O QYHFIVBSNOWOCQ-UHFFFAOYSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863618627 DE3618627A1 (de) | 1986-06-03 | 1986-06-03 | Arzneimittel mit dopaminerger wirkung |
| EP87106390A EP0248215B1 (de) | 1986-06-03 | 1987-05-02 | Arzneimittel mit dopaminerger Wirkung |
| DE8787106390T DE3786425D1 (de) | 1986-06-03 | 1987-05-02 | Arzneimittel mit dopaminerger wirkung. |
| AT87106390T ATE91235T1 (de) | 1986-06-03 | 1987-05-02 | Arzneimittel mit dopaminerger wirkung. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863618627 DE3618627A1 (de) | 1986-06-03 | 1986-06-03 | Arzneimittel mit dopaminerger wirkung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3618627A1 DE3618627A1 (de) | 1987-12-10 |
| DE3618627C2 true DE3618627C2 (show.php) | 1992-02-06 |
Family
ID=6302174
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19863618627 Granted DE3618627A1 (de) | 1986-06-03 | 1986-06-03 | Arzneimittel mit dopaminerger wirkung |
| DE8787106390T Expired - Fee Related DE3786425D1 (de) | 1986-06-03 | 1987-05-02 | Arzneimittel mit dopaminerger wirkung. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8787106390T Expired - Fee Related DE3786425D1 (de) | 1986-06-03 | 1987-05-02 | Arzneimittel mit dopaminerger wirkung. |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP0248215B1 (show.php) |
| AT (1) | ATE91235T1 (show.php) |
| DE (2) | DE3618627A1 (show.php) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10206390A1 (de) * | 2002-02-15 | 2003-08-28 | Bionorica Ag | Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten |
| DE10304590A1 (de) * | 2003-02-05 | 2005-01-27 | Heinz Kiefer | Verwendung eines Arzneimittels in Kapselform zur Behandlung klimakterischer Beschwerden mit Störungen des sexuellen Appentenzverhaltens, dadurch gekennzeichnet, daß es eine Kombination von Agnicastifructus, Cimicifugaeracemosaerhizoma und D-alpha-Tocopherol enthält |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1883092A (en) * | 1991-06-07 | 1993-01-08 | Krewel-Werke Gmbh | Concentrated and/or dry plant extracts |
| DE19844836A1 (de) * | 1998-09-30 | 2000-04-20 | Hexal Ag | Pharmazeutisch, wirksames, pflanzliches Präparat zur Behandlung von Migräne |
| DE19920491A1 (de) * | 1999-05-05 | 2000-11-16 | Claus Rolf | Medikament zur Therapie der männlichen Infertilität |
| US20020068100A1 (en) * | 2000-10-12 | 2002-06-06 | Bioriginal Food & Science Corporation | Combination therapy for premenstrual symptoms |
-
1986
- 1986-06-03 DE DE19863618627 patent/DE3618627A1/de active Granted
-
1987
- 1987-05-02 EP EP87106390A patent/EP0248215B1/de not_active Expired - Lifetime
- 1987-05-02 DE DE8787106390T patent/DE3786425D1/de not_active Expired - Fee Related
- 1987-05-02 AT AT87106390T patent/ATE91235T1/de not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10206390A1 (de) * | 2002-02-15 | 2003-08-28 | Bionorica Ag | Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten |
| DE10304590A1 (de) * | 2003-02-05 | 2005-01-27 | Heinz Kiefer | Verwendung eines Arzneimittels in Kapselform zur Behandlung klimakterischer Beschwerden mit Störungen des sexuellen Appentenzverhaltens, dadurch gekennzeichnet, daß es eine Kombination von Agnicastifructus, Cimicifugaeracemosaerhizoma und D-alpha-Tocopherol enthält |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0248215B1 (de) | 1993-07-07 |
| DE3786425D1 (de) | 1993-08-12 |
| EP0248215A3 (en) | 1989-10-04 |
| DE3618627A1 (de) | 1987-12-10 |
| EP0248215A2 (de) | 1987-12-09 |
| ATE91235T1 (de) | 1993-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69830578T2 (de) | Forskolin zur entwicklung magerer körpermasse | |
| DE10337458A1 (de) | Verbesserungen bei der Extraktion von pharmazeutisch aktiven Komponenten aus Pflanzenmaterialien | |
| DE69633345T2 (de) | Verfahren zur herstellung von rg3 und rg5 ginsenosiden | |
| EP1608388B1 (de) | Verfahren zur herstellung eines extraktes aus efeublättern | |
| DE19781489C2 (de) | Verfahren zur Verarbeitung von Ginseng und mittels dieses Verfahrens erhaltener verarbeiteter Ginseng | |
| DE3618627C2 (show.php) | ||
| EP1663269B1 (de) | Verfahren zur herstellung eines lagerstabilen extraktes aus efeublättern, sowie ein nach diesem verfahren hergestellter extrakt | |
| DE69009673T2 (de) | Pflanzlichen Saft und Protoplasten enthaltende Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendungen, insbesondere auf dem Gebiet der Phytotherapie. | |
| DE60308045T2 (de) | Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes | |
| EP0154872A2 (de) | Verfahren zur Herstellung flavonreicher Kamillenextrakte | |
| DE2124023C3 (de) | Verfahren zur selektiven Gewinnung von Vinblastin, Vinleurosin und Vincristin oder von deren Sulfaten | |
| EP0175185A2 (de) | Verfahren zur Gewinnung haltbarer wirkstoffreicher Kamillenextrakte | |
| DE3152847C2 (en) | Ribulose-1,5-diphosphate carboxylase and process for obtaining it | |
| EP0508330B1 (de) | Verfahren zur Herstellung von Extrakten aus Rhizoma Petasitidis mit Kohlendioxid | |
| DE2201991C2 (de) | Verfahren zur Gewinnung von steroidalen Insektenhäutungshormonen | |
| DE10246884A1 (de) | Verfahren zur Herstellung von Extrakten aus Rhizoma Petasitidis | |
| WO2013007807A1 (de) | Ausgewählte cimicifuga-fraktionen zur behandlung von osteoporose | |
| CN110477037B (zh) | 一种植物源农药组合物及其制备方法和应用 | |
| DE4102054A1 (de) | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe | |
| DE3806210A1 (de) | Kamille | |
| DE3542756C2 (show.php) | ||
| AT400673B (de) | Verfahren für die herstellung von heilpflanzenextrakten | |
| CN117046155B (zh) | 一种积雪草滤液及其制备方法和应用 | |
| US3066074A (en) | Extract of bixa orellana plant for use as a pharmaceutical | |
| EP0298148B1 (de) | Verfahren zur Gewinnung von Beta-aescinreichen Extrakten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |